Static adhesion assay.

<p>The same method as for <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111518#pone-0111518-g001" target="_blank">Fig. 1</a> but with the addition of 5 µg/ml ofmAbs 15.2 (A), My13 (B), 8.46A (C) and BBIG-I1 (D) prior the IE incubation with ICAM-1^Ref. The results show the percentage of binding in the presence of ICAM-1 mAb compared to the no mAb treatment (A), and the bars represents SE (n>3).</p

Static adhesion assay, 2 µl spots at 50 µg/ml protein concentration were placed onto 6 cm dishes and standard protein static binding assays carried out with IE suspended in binding buffer at a parasitaemia of 3% and a haematocrit of 1%.

<p>The results show the mean of binding (IE/mm²) (Figure 1A) and %ICAM-1^Ref binding (Figure 1B–E), and the bars represents SE (n≥3).</p

Flow endothelial cell adhesion assay.

<p>HDMEC seeded on channels pre-coated with fibronictin; IE were passed on confluent cells for five minutes followed by washing by binding buffer for two minutes before counting 6 fields in two different channels. The parasitaemia was 3% and a haematocrit of 2%. The results show the mean of binding with no inhibitory mAbs (A) and the % binding on treatment with 5 µg/ml of 15.2 anti-ICAM-1 (B) and 5 µg/ml IV-C7 anti-CD36 (C) mAbs compared to no mAb treatment. The bars represents SE (n≥3).</p